Mylan (MYL) Gains Early After Taking Action on EpiPen Pricing
- Wall St. slips as countdown to Trump's swearing-in begins
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- Apple (AAPL) PT Raised to $140 at BofA/Merrill Lynch; iPhone 8 Will be 'Super-Long' Cycle
- Morgan Stanley Upgrades Tesla Motors (TSLA) to Overweight
- CP's (CP) Outgoing CEO Hunter Harrison, Activist Paul Hilal Said Set to Target CSX Corp. (CSX)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
After dropping sharply over the past few sessions on headline risk related to EpiPen pricing, Mylan (NASDAQ: MYL) shares are gaining 3% early after the company announced plans to reduce patient cost through savings card which will cover up to $300 for their EpiPen 2-Pak.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Perrigo (PRGO) short duration January calls active
- Target (TGT) volatility flat into Goldman Sachs downgrade to Sell
- 3D Systems (DDD) calls with two-days to expiration active
Create E-mail Alert Related CategoriesTrader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!